Constitutive activation of the class III receptor tyrosine kinase, FLT3, plays important roles in leukemogenesis. [1] [2] [3] [4] Internal tandem duplications in the juxtamembrane region (FLT3-ITD) or point mutations in the kinase domain (FLT3-PM) lead to constitutively activated FLT3. [5] [6] [7] FLT3 is also activated by coexpression of FLT3 ligand (FL) through intracrine, paracrine, and/or autocrine pathways. [8] [9] [10] The presence of FLT3-ITD mutations is associated with a poor prognosis in acute myelogenous leukemia (AML). 11-14 Activated FLT3 mediates signaling through at least 3 major downstream signaling pathways: signal transducers and activators of transcription (STAT5), PI3K/Akt, and Ras/mitogen-activated protein (MAP) kinase. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] These signaling pathways have overlapping roles in cell differentiation, proliferation, and survival. FLT3 is expressed in most acute leukemias, including 94% of B-lineage acute lymphoblastic leukemia (ALL), 34% of T-lineage ALL, and 89% of AML cases. [26] [27] [28] These observations strongly suggest FLT3 as a candidate for molecularly targeted therapy.
Introduction
Constitutive activation of the class III receptor tyrosine kinase, FLT3, plays important roles in leukemogenesis. [1] [2] [3] [4] Internal tandem duplications in the juxtamembrane region (FLT3-ITD) or point mutations in the kinase domain (FLT3-PM) lead to constitutively activated FLT3. [5] [6] [7] FLT3 is also activated by coexpression of FLT3 ligand (FL) through intracrine, paracrine, and/or autocrine pathways. [8] [9] [10] The presence of FLT3-ITD mutations is associated with a poor prognosis in acute myelogenous leukemia (AML). [11] [12] [13] [14] Activated FLT3 mediates signaling through at least 3 major downstream signaling pathways: signal transducers and activators of transcription (STAT5), PI3K/Akt, and Ras/mitogen-activated protein (MAP) kinase. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] These signaling pathways have overlapping roles in cell differentiation, proliferation, and survival. FLT3 is expressed in most acute leukemias, including 94% of B-lineage acute lymphoblastic leukemia (ALL), 34% of T-lineage ALL, and 89% of AML cases. [26] [27] [28] These observations strongly suggest FLT3 as a candidate for molecularly targeted therapy.
In fact, a number of FLT3 tyrosine kinase inhibitors (TKIs) have been developed. Some of the best studied to date include CEP-701 (lestaurtinib), PKC412, MLN518, SU11248 (sunitinib malate), and AG1295. 23, [29] [30] [31] [32] [33] Although these inhibitors vary in their potency and selectivity for FLT3, all are able to induce cytotoxicity in FLT3-expressing cells in vitro and/or in vivo. Furthermore, clinical trials with some of these inhibitors have demonstrated their ability to decrease peripheral blood and bone marrow blast counts in some patients. [34] [35] [36] CEP-701 is currently being tested on relapsed patients with FLT3 mutant AML in a randomized phase 2 clinical trial in combination with chemotherapy.
Although FLT3 inhibitors demonstrate preclinical and clinical activity, they possess a number of limitations. Clinical trials have revealed that FLT3 TKIs used as single agents are able to significantly reduce peripheral blood and bone marrow blasts only in a minority of patients, and the effect is transitory. [34] [35] [36] This may be due to achieving insufficient levels of FLT3 inhibition in these patients, a lack of dependence of these cells on FLT3 signaling for proliferation and survival, and/or selection of resistant cell populations. Furthermore, most cases of AML and ALL do not express mutant FLT3, and it is unclear to what degree these cells depend on FLT3 signaling for sustaining the leukemic phenotype. At drug concentrations necessary to inhibit FLT3 phosphorylation past a critical threshold required to induce cytotoxicity, a varying spectrum of other kinases are frequently also inhibited, which can lead to toxicities.
Even when cells are dependent on FLT3 signaling for survival and proliferation, prolonged exposure to TKIs are likely to select for resistant clones, as has been seen with imatinib mesylate (Gleevec), a TKI targeting BCR-ABL in chronic myelogenous leukemia. 37 Cells have the potential to develop several mechanisms of resistance: (1) Cells may acquire FLT3 mutations that prevent drug binding. 38, 39 ( 2) Expression of cell-surface transport proteins may reduce the intracellular drug concentration and thereby interfere with FLT3 inhibition. (3) FLT3 overexpression may reduce the efficacy of FLT3 TKIs to inhibit target. (4) Cells can become FLT3 independent by activating compensatory signaling pathways.
Anti-FLT3 immunotherapy is an alternative to small molecule inhibitors. Antibodies are very specific and therefore are usually less toxic than TKIs and have the potential added advantage of recruiting the host's immune system in clearing leukemic cells. We recently demonstrated that IMC-EB10, an unconjugated monoclonal antibody (mAb) that binds FLT3, blocks (FL) binding and in turn affects downstream STAT5, Akt, and MAPK signaling pathways. [40] [41] [42] Although IMC-EB10 has no in vitro cytotoxicity, IMC-EB10 is able to prolong survival and reduce the level of engraftment of AML and ALL-derived cell lines and of primary samples in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice without affecting the engraftment of normal cord blood CD34 ϩ human stem cells. 41, 42 Unlike TKIs, the in vivo efficacy of IMC-EB10 depends on antibody-dependent cellmediated cytotoxicity (ADCC) and is therefore not dependent on inhibition of FLT3 signaling. 41, 42 To investigate some of the mechanisms used by human leukemic cells to overcome FLT3 TKI-mediated cytotoxicity, we selected for resistant cells by exposing 3 AML-or ALL-derived FLT3-dependent human cell lines to increasing concentrations of FLT3 inhibitors. We then examined signal transduction in the resistant cells. We also investigated whether the TKI-resistant cell lines would also be resistant to anti-FLT3 mAb treatment.
Methods and materials

Reagents
Mouse monoclonal antiphosphotyrosine antibody (4G10) and recombinant protein A-agarose were purchased from Upstate Biotechnology (Lake Placid, NY). Rabbit anti-P-FLT3, anti-P-STAT5, anti--P-Akt, anti-FLT3, anti-Akt, anti-P-STAT1, anti-STAT1 anti-P-MAPK p44/42, and anti-MAPK p44/42 antibodies were obtained from Cell Signaling Technologies (Beverly, MA). Rabbit anti-FLT3 and anti-STAT5 antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Humanized anti-EGFR antibody, IMC-C225 (cetuximab; ImClone Systems, New York, NY) and IMC-EB10 were generously provided by ImClone Systems. Horseradish peroxidase-conjugated secondary antibody and enhanced chemiluminescence (ECL) detection system were purchased from Amersham (Arlington Heights, IL).
FLT3 inhibitors, CEP-5214 and CEP-701, were generously provided by Cephalon (Frazer, PA). PKC412 was generously provided by Novartis (East Hanover, NJ). AG1295 was purchased from Sigma-Aldrich (St Louis, MO). The following human ligands were obtained from PeproTech (Rocky Hill, NJ): IL-2, IL-3, IL-6, IL-11, GM-CSF, SCF, and EGF. Insulin, IGF-1, and GDNF human ligands were obtained from Santa Cruz Biotechnology. MEK inhibitor (U0126) was obtained from Promega (Madison, WI) and PI3K inhibitor (LY294002) from Cell Signaling Technologies.
Cell lines
Human cell lines were cultured in RPMI-1640 (GIBCO, Rockville, MD), supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gimini Bio-Products, Woodland, CA) and penicillin/streptomycin (GIBCO) at 37°C with 5% CO 2 . The Molm14 cell line was derived from an AML primary sample and expresses FLT3-ITD and MLL-AF9 mutant proteins. Both Hb1119 and SEM-K2 cells are derived from ALL primary samples. Hb1119 cells express FLT3-D835H and MLL-ENL mutant protein, whereas SEM-K2 cells express amplified wild-type FLT3 along with the MLL-AF4 fusion protein.
Development of FLT3 TKI-resistant cell lines
Log phase growing MOLM14, Hb1119, and SEM-K2 cell lines were cocultured with increasing concentrations of CEP-5214 or CEP-701 for 2 to 4 months. Cell cultures were deemed resistant when cells proliferated in the presence of 50 to 120 nM CEP-5214 or CEP-701, depending on the sensitivity of the parent cell line to the FLT3 TKI. The selection for resistant cells was repeated a total of 4 separate times for each cell line to ensure reproducibility. FLT3 TKI-resistant cell lines were grown without CEP-5214 or CEP-701 for at least 2 days prior to experimentation.
Human primary samples
Human samples from patients with AML and patients with ALL were obtained under an institutional review board-approved protocol at the Sidney Kimmel Cancer Center at Johns Hopkins Hospital. Informed consent was provided according to the Declaration of Helsinki. Leukemic blasts were separated by Ficoll-Hypaque (Amersham, Piscataway, NJ) density gradient centrifugation as previously described. 43 
Western blot analysis
Western blots were performed as previously described. 41, 42 Cell viability assays MTT (Roche, Indianapolis, IN) and annexin V (BD-Bioscience, Palo Alto, CA) binding assays were performed according to the manufacturer's recommendations. Cell lines were plated at 300 000 cells/mL and primary samples at 5 ϫ 10 6 cells/mL for the MTT and annexin V binding assay. Cells were treated as indicated for 48 hours. MTT results are presented as the percentage of OD 570 of the control sample not treated with a FLT3 TKI.
PCR: identification of FLT3 and MLL (mixed-lineage leukemia) mutations
Total RNA was isolated using the RNeasy Mini kit (Qiagen Sciences, Valencia, CA) and converted into cDNA using Superscript III (Invitrogen, Carlsbad, CA) and the manufacturer's protocol. Polymerase chain reaction (PCR) used primers spanning the FLT3 mutation or MLL translocation sites and 40 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 60 seconds. The primer sequences will be provided on request. Half of the PCR product for FLT3-D835H analysis was digested with EcoRV (New England BioLabs, Beverly, MA). PCR products were run on a 2% agarose gel.
Heteroduplex analysis: kinase and phosphatase mutational screen
Total RNA and genomic DNA were separated by Trizol (Invitrogen) extraction, and RNA was further isolated with the RNeasy Kit (Qiagen Sciences). cDNA was prepared from RNA using Superscript III. PCR primers were synthesized to amplify the catalytic and juxtamembrane domain (where applicable) of each of the genes to be screened (see Figure  S1 , available on the Blood website; see the Supplemental Figure link at the top of the online article). Each primer pair was previously optimized to ensure a PCR product. Using a denaturation step of 95°C followed by a slowly decreasing temperature gradient (80°C-25°C), PCR products were annealed and formed duplexes. Capillary electrophoresis was performed on the SpectruMedix Reveal machine (SpectruMedix, State College, PA) using temperature gradients of 45°C to 55°C and 50°C to 60°C. The CCD camera of the SpectruMedix Reveal machine captures images of the product in the capillary, and the software (SpectruMedix Revelation) converts these images into peaks, based on the intensity of the ethidium bromide signal. The peaks were analyzed to determine which samples contained heteroduplexes that might indicate changes in the DNA sequence between the 2 strands. These samples were further analyzed by sequencing to determine the nature of the change. If mutations were found, they were confirmed using the original RNA and genomic DNA.
Quantitative real-time PCR (Q-PCR)
Q-PCR was performed as previously described. 42 GAPDH was used to normalize gene expression.
DNA construct and lentiviral transduction
HA-tagged full-length cDNA coding for wt N-Ras or N-Ras-G12V was obtained from the UMR cDNA Resource Center (www.cdna.org) and cloned into a lentiviral vector with an EF1 promoter and a CMV promoter driving GFP expression. This lentiviral vector was kindly provided by Linzhao Cheng. Lentiviral constructs along with VSVG and PMV helper plasmids were transfected into 293T cells using Lipofectamine 2000 (Invitrogen). The supernatant was collected for 48 hours, starting 16 hours after tranfection of 293T cells. Lentivirus containing supernatant was concentrated using Centricon Plus-70 filters (Milipore, Billerica, MA). Cells were transduced with a given lentivirus in media containing 8 g/mL Polybrene (Sigma-Aldrich) for 48 hours. At 96 hours after transduction, cells with equal levels of GFP expression were sorted on a BD FACSvantage SF cell sorter (BD-Bioscience).
Flow cytometry
Flow cytometry was performed as previously described. 41, 42 In vivo models of human leukemia: engraftment and survival NOD/SCID mice were bred at the Johns Hopkins University School of Medicine. Mice were sublethally irradiated (280 cGy) and injected with 0.5 ϫ 10 6 cells in 200 L PBS via tail-vein injection. Mice were given intraperitoneal injections of 400 g IMC-C225 or IMC-EB10 at 24, 72, and 120 hours after cell injection. All animal procedures were conducted in conformity with institutional guidelines.
Results
Culture of leukemia-derived cell lines with CEP-5214 or CEP-701 leads to FLT3 TKI cross-resistance
To investigate mechanisms of drug resistance, the human leukemiaderived cell lines, SEM-K2, Molm14, and Hb1119, expressing amplified wt FLT3, FLT3-ITD, and FLT3-D835H, respectively, were cocultured with increasing concentrations of CEP-5214 or CEP-701. After 2 to 4 months of coculture with FLT3 TKIs, these cell lines were able to proliferate in the presence of 50 to 120 nM CEP-701 or CEP-5214, although their growth rates were somewhat slower in the presence of FLT3 TKIs than in their absence (data not shown). Resulting resistant cell lines are named with an "(R)" followed by the FLT3 inhibitor used during coculture (eg SEM(R)5214). PCR analysis of FLT3 mutations, MLL translocations, and cytogenetic analysis confirmed that the FLT3 TKIresistant cell lines were derived from the parental line and still expressed those defining characteristics after prolonged drug exposure (data not shown).
Both the MTT and annexin V binding assays were used to determine the cytotoxic effects of CEP-5214, CEP-701, PKC412, and AG1295 on the sensitive parental versus resistant cell lines. MTT assays revealed that prolonged coculture of SEM-K2, Molm14, and Hb1119 cell lines with CEP-5214 or CEP-701 led to crossresistance to CEP-5214, CEP-701, PKC412, and, a structurally dissimilar FLT3 inhibitor, AG1295 ( Table 1 Several samples from patients with AML and patients with ALL were also examined to determine whether a similar phenomenon might explain resistance to FLT3 TKIs that we have observed previously in approximately 20% of FLT3-ITD AML samples. 29, 34 Treatment of a FLT3 TKI-sensitive primary sample (IC 50 value Ͻ 50 nM CEP-701) with CEP-701 led to inhibition of FLT3 phosphorylation that correlated with inhibition of downstream signaling pathways ( Figure 2E ; data not shown). However, primary samples resistant to CEP-701-induced cytotoxicity (IC 50 value Ͼ 50 nM CEP-701) exhibited continued phosphorylation of STAT5 and/or Akt and/or MAPK signaling proteins even with inhibition of FLT3 phosphorylation ( Figure 2E ; data not shown). A lack of P-STAT5 and P-Akt was observed in 2 tested primary samples, possibly because of deficiencies in upstream signaling proteins responsible for their activation.
Data from the resistant cell lines and primary samples thus suggest that alternative pathways not inhibited by FLT3 TKIs may sustain the activation of downstream signaling pathways that provide compensatory survival/proliferation signals during inhibition of FLT3 phosphorylation. Thus, prolonged exposure to FLT3 TKIs selects for FLT3-independent clones. Because we never observed the spontaneous selection for mutations within wt FLT3, FLT3-ITD, or FLT3-D835H that would render them resistant to inhibition of kinase activity, this may be a much more frequent mechanism to explain why patients' responses to FLT3 TKIs are often short lived. For personal use only. on April 13, 2017. by guest www.bloodjournal.org From
Overexpression of wild-type RTKs may play a role in resistance to FLT3 TKIs
Overexpression of RTKs may contribute to the activation of compensatory downstream signaling pathways. To explore this possibility, the expression level of RTKs was determined using Q-PCR analysis using cDNA from FLT3 TKI-sensitive and -resistant cell lines with expression normalized to GAPDH expression. These studies revealed that most FLT3 TKI-resistant cell lines overexpress a number of RTKs compared with FLT3 TKI-sensitive cell lines ( Figure 5 ).
Ligand stimulation of receptor tyrosine kinases (RTKs) do not account for the observed resistance to FLT3 TKIs
Ligand-mediated RTK phosphorylation could also maintain the activation of various signaling pathways, including Akt and/or MAPK, during inhibition of FLT3 phosphorylation leading to FLT3-independent growth. To test this hypothesis, the parental SEM-K2, Molm14, and Hb1119 cell lines were treated with 10 human ligands (IL-2, IL-3, IL-6, IL-11, GM-CSF, SCF, EGF, insulin, IGF-1, and GDNF) and were then exposed to various concentrations of CEP-701. Receptors that bind a number of these ligands were confirmed to be expressed on SEM-K2, Molm14, and/or Hb1119 cell lines by Q-PCR and Western blotting ( Figure 5 ; data not shown). MTT assays demonstrated that ligand stimulation of these 10 RTKs did not result in significant resistance to CEP-701 treatment, even when cells were simultaneously stimulated with a combination of 2 to 4 ligands (data not shown). To determine whether other ligands might play a role in resistance to FLT3 TKIs, the parental SEM-K2, Molm14, and Hb1119 cell lines were grown in human bone marrow stromal cell-conditioned media and treated with CEP-701. Conditioned media resulted in only minimal changes to CEP-701-mediated cytotoxicity (data not shown). Overall, these data indicate that resistance to FLT3 TKIs is not Figure 6C ). In addition, annexin-V/7-AAD binding assays demonstrated that inhibition of FLT3 along with the PI3K and/or MEK signaling pathways resulted in a greater induction of apoptosis in FLT3 TKI-resistant M14(R)5214 and M14(R)701 cell lines that constitutively activate these pathways than FLT3 TKI treatment alone ( Figure 6E ). Taken together, these data demonstrate that activation of the Akt and/or MAPK signaling pathways through FLT3-independent pathways play a role in resistance to FLT3 TKIs.
Treatment with PI3K and/or MEK inhibitors did not result in a significant increase in cytotoxicity if Akt and MAPK proteins were already dephosphorylated because of FLT3 TKI treatment. This was seen with the SEM-K2, SEM(R)701, Molm14, Hb1119, and Hb(R)701 cell lines (Figure 2A, lanes 1-5, 11-15 ; Figure 2B , lanes 1-5; Figure 2C , lanes 1-5, 11-15; Figure 6B ; data not shown). Phosphorylation of Akt and MAPK was fully inhibited in cells treated with 5 M PI3K and MEK inhibitors, and no increase in cytotoxicity was observed when a higher concentration of PI3K or MEK inhibitor was used ( Figure 6A ; data not shown). This indicates that the increase in cytotoxicity observed when PI3K and/or MEK inhibitors are combined with FLT3 TKIs is likely due to inhibition of Akt and/or MAPK signaling pathways and not likely due to off target inhibition.
Inhibition of constitutively activated Akt or MAPK signaling pathways in FLT3 TKI-resistant primary samples does not restore sensitivity to FLT3 inhibition
To determine whether inhibition of constitutively activated Akt and/or MAPK sensitizes FLT3 TKI-resistant primary samples to FLT3 inhibition, 3 FLT3 TKI-resistant AML or ALL primary samples were used. MTT assays revealed that combining PI3K and/or MEK inhibitors with FLT3 TKIs does not result in increased cytotoxicity in the tested primary samples (data not shown). Western blot analysis confirmed that treatment of FLT3 TKI-resistant primary samples with PI3K and MEK inhibitors inhibited the phosphorylation of Akt and MAPK, respectively (data not shown).
FLT3 TKI-resistant cell lines still respond to anti-FLT3 mAb treatment in NOD/SCID mice
The data shown in these studies indicate that prolonged exposure to FLT3 TKIs often selects for cells that are FLT3 independent; therefore, inhibition of FLT3 fails to induce cytotoxicity. We have previously shown that the efficacy of anti-FLT3 mAb treatment does not depend on FLT3 inhibition and thus could still prove cytotoxic to FLT3 TKI-resistant cell lines. This hypothesis was tested by injecting NOD/SCID mice via tail vein with SEM-K2, Molm14, or FLT3 TKI-resistant cells derived from SEM-K2 or Molm14 cell lines. Mice were given intraperitoneal injections of 400 g IMC-C225 or IMC-EB10 at 24, 72, and 120 hours after cell injection. Fluorescence-activated cell sorting (FACS) analysis of the bone marrows 30 days after cell injection revealed that IMC-EB10 treatment reduced the engraftment of SEM-K2 as well as the FLT3 TKI-resistant SEM(R)5214 and SEM(R)701 cell lines to below 1% ( Figure 7A ). In contrast, mice treated with the control mAb, IMC-C225, had 50% to 70% human cells in their bone marrow. Furthermore, IMC-EB10 treatment significantly prolonged the survival of NOD/SCID mice injected with Molm14, M14(R)5214, and M14(R)701 cell lines compared with control treatment ( Figure 7B ). IMC-EB10 is not cytotoxic to Hb1119 cells in vivo; therefore, it was not included in these studies. 42 
Discussion
Clinical trials using FLT3 TKIs have shown clinical responses in some patients, and the responses typically persist for only a few months. [34] [35] [36] The inability of FLT3 TKIs to sustain suppression of leukemic blasts in these patients suggests that prolonged exposure to FLT3 TKIs may select for resistant cell populations. Several FLT3 mutations occurring with FLT3-ITD mutants were found to render transfected Ba/F3 cells resistant to SU5614 and/or PKC412. 39, 44, 45 Furthermore, activation loop mutations of FLT3 have variable sensitivities to MLN518, AG1296, PKC412, and SU5614. 33, 46 However, to date, only a single patient with an acquired FLT3 mutation leading to FLT3 TKI resistance has been identified in clinical trials of these agents. 38 Therefore, the inability of FLT3 TKIs to suppress the levels of leukemic blasts in patients for prolonged periods of time is likely due to alternative resistance mechanisms.
To investigate mechanisms of FLT3 TKI resistance in human leukemic cell lines, we cocultured SEM-K2, Molm14, and Hb1119 cells, each sensitive to FLT3 TKIs, with increasing concentrations of CEP-5214 or CEP-701 for 2 to 4 months. The resulting cell lines exhibited cross-resistance to all tested FLT3 TKIs. Western blot analysis revealed that FLT3 TKI treatment of FLT3 TKI-sensitive and -resistant cell lines resulted in inhibition of FLT3 phosphorylation. Thus, in this setting, resistance to FLT3 TKIs is not due to FLT3 mutations interfering with drug binding or p-glycoproteinmediated export of FLT3 TKIs across the plasma membrane. Furthermore, sequencing of FLT3 confirmed no mutations within the resistant cell lines, and there was no increase in expression of p-glycoprotein observed by flow cytometry. Western blots and flow cytometry also confirmed that FLT3 TKI-resistant cell lines were not overexpressing FLT3 as a mechanism of drug resistance.
Western blot analysis of FLT3 TKI-resistant cell lines and primary samples did show continued activation of a number of signaling pathways normally dependent on FLT3 signaling, despite inhibition of FLT3. This pattern was previously observed in a number of FLT3 TKI-resistant primary samples. 29, 47 Furthermore, recent studies reveal that inhibition of FLT3 phosphorylation does not always correlate with induction of cytotoxicity. 48, 49 Therefore, continued activation of these pathways despite inhibition of FLT3 phosphorylation in FLT3 TKI-resistant cells suggests that FLT3-independent pathways phosphorylate/activate STAT1, STAT5, Akt, and/or MAPK along with possibly other unidentified signaling proteins and maintain the expression of genes that play a role in cell survival/proliferation. Activation of these and/or other signaling proteins through pathways not inhibited by FLT3 TKIs may explain the observed resistance to FLT3 TKIs.
In fact, inhibition of the PI3K/Akt and/or MEK/MAPK pathways by their respective inhibitors increased the sensitivity of FLT3 TKI-resistant cell lines to CEP-5214 and CEP-701. The data indicate that both of these pathways independently contribute to the observed resistance to FLT3 TKIs. However, FLT3 TKI-resistant cell lines vary in their degree of dependence on a given signaling pathway and may depend on more than just the Akt and MAPK signaling pathways for survival. This might explain why inhibition of the Akt and/or MAPK signaling pathways does not completely restore FLT3 TKI sensitivity. Furthermore, the lack of constitutive activation of Akt and/or MAPK in SEM(R)701 and Hb(R)701 cell lines, activation of a new signaling pathway (STAT1) in Hb(R)701 cells, and continued activation of STAT5 in some primary resistant samples supports the conclusion that pathways other than Akt and MAPK also play a role in FLT3 TKI resistance. Moreover, the observation that inhibition of Akt and/or MAPK phosphorylation in FLT3 TKI-resistant primary samples does not sensitize these cells to FLT3 TKIs suggests that other signaling pathways also play a role in FLT3 TKI resistance.
Activation of compensatory survival pathways may be due to mutations in a number of upstream signaling proteins, including pathway regardless of the upstream protein(s) responsible for their activation. However, inhibiting downstream pathways is also more likely to prove cytotoxic to normal cells that use these pathways for growth and survival. In contrast to TKIs, IMC-EB10, as a single therapeutic agent, still proved cytotoxic to FLT3 TKI-resistant cell lines in vivo. Anti-FLT3 mAb treatment of FLT3-expressing leukemias could potentially overcome a variety of drug resistance mechanisms because IMC-EB10-mediated cytotoxicity is not dependent on the phosphorylation status of FLT3 or downstream signaling proteins.
In summary, we demonstrate that prolonged exposure of human leukemic cell lines to FLT3 TKIs most frequently results in FLT3 independence and cross-resistance to multiple FLT3 TKIs without mutations in FLT3. Resistance to FLT3 TKIs is mediated, at least in some FLT3 TKI-resistant cell lines, via phosphorylation of downstream signaling proteins by FLT3-independent pathways. In 2 cases, this was due to selection of activating Ras mutations. Furthermore, treatment of NOD/SCID mice with anti-FLT3 mAbs is still effective in reducing the engraftment and prolonging survival when injected with FLT3 TKI-resistant cell lines. We hypothesize that combining FLT3 TKIs with PI3K and/or MEK inhibitors and/or anti-FLT3 mAbs may reduce the incidence of resistance and thereby increase the efficacy of FLT3 TKIs in patients. or IMC-EB10, given every other day. Mice were killed 30 days after cell injection, and bone marrow cells were obtained from femurs. Cells harvested from femurs were stained with hCD19-FITC, mCD45-PE, and hCD45-APC, and human engraftment was determined by flow cytometry. (B) NOD/SCID mice, in groups of 10, were injected with 0.5 ϫ 10 6 Molm14, M14(R)5214, or M14(R)701 cells via tail-vein injection. Starting 24 hours after cell injection, mice were injected intraperitoneally a total of 3 times with 400 g IMC-C225 or IMC-EB10, given every other day. Mice were monitored daily for survival.
